Crown Laboratories hikes offer price for Revance to $3.65/share, extends existing tender offer
Crown Laboratories Tuesday increased its offer price to acquire Revance Therapeutics (NASDAQ:RVNC) to $3.65 per share, a $0.55 per share increase. Improved offer unanimously approved by Revance ...
Revance Therapeutics soars after Crown Labs raises offer to $3.65 a share
Revance Therapeutics (NASDAQ:RVNC) jumped 11% in premarket trading after Crown Laboratories increased its offer above Teoxane ...
Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr
Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced ...
Crown Labs Proposed Higher Revance Bid to Save Deal
Crown Laboratories plans to raise its takeover price for Revance Therapeutics to $3.65 a share, topping a rival $3.60-a-share bid from Swiss medical-aesthetics company Teoxane.